Skip to main content
. 2007 Dec;1(4):377–392.

Table 7.

Zolinza (vorinostat) Study 1: Baseline patient characteristics (all patients as treated)

Characteristics CTCL stage, n (%) Vorinostat (n = 74)
IB (14.9%)
IIA 2 (2.7%)
IIB 19 (25.7%)
III 22 (29.7%)
IVA 16 (21.6%)
IVB 4 (5.4%)
Clinical Characteristics
Number of prior systemic treatments, median (range) 3.0 (1.0, 12.0)